What question did this study set out to answer?

To evaluate the efficacy and safety of asciminib in patients with chronic myeloid leukaemia in blast phase.

December 8, 2025Blood

Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of asciminib in patients with chronic myeloid leukaemia in blast phase.
Retrospective analysis of adult patients treated with asciminib at Queen Mary Hospital, Hong Kong.
Data collected on demography, treatment regimens, and clinical outcomes.
Assessments included BCR::ABL1 transcript levels and Sanger sequencing for mutations.
71% of patients achieved overall response with asciminib treatment.
66.7% one-year overall survival reported at median follow-up of 8 months.
Asciminib was well tolerated with mild toxicities and only minor adverse events observed.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis shows asciminib improves molecular response in chronic myeloid leukaemia blast phase patients, indicating adjunctive therapy potential.

Cite This Study

Ip et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfc9 https://doi.org/10.1182/blood-2025-7297

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows asciminib improves molecular response in chronic myeloid leukaemia blast phase patients, indicating adjunctive therapy potential.

Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase

Key Points

Discussion

Implication

Cite This Study

Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider